Cynapsus Therapeutics
Cynapsus is a specialty central nervous system, or CNS, pharmaceutical company developing a fast-acting, easy-to-use, sublingual thin film for the potential treatment for on-demand management of debilitating OFF episodes associated with Parkinson’s disease (PD). The Company successfully completed a Phase 2 clinical trial for its product candidate, APL-130277, a sublingual formulation of apomorphine hydrochloride, or apomorphine. Apomorphine is the only molecule approved for acute, intermit
Basic Information
- Category: pharmaceutical industry
- Website: https://www.cynapsus.ca/
Documented Facts
- Inception (Wikidata): 1984 (Source 2: Wikidata Q5199886, revision 1936224040)
- Industry (Wikidata; date unspecified): pharmaceutical industry (Source 2: Wikidata Q5199886, revision 1936224040; Source 3: Wikidata label: Q507443, revision 2542338100)
- Headquarters location (Wikidata; date unspecified): Toronto (Source 2: Wikidata Q5199886, revision 1936224040; Source 4: Wikidata label: Q172, revision 2552957866)
- Country (Wikidata; date unspecified): Canada (Source 2: Wikidata Q5199886, revision 1936224040; Source 5: Wikidata label: Q16, revision 2555105353)
- Official website (Wikidata; date unspecified): https://www.cynapsus.ca/ (Source 2: Wikidata Q5199886, revision 1936224040)
Evidence and Sources
- Cynapsus Therapeutics — Official Website (official)
- Wikidata Q5199886, revision 1936224040 (knowledge-base)
- Wikidata label: Q507443, revision 2542338100 (knowledge-base)
- Wikidata label: Q172, revision 2552957866 (knowledge-base)
- Wikidata label: Q16, revision 2555105353 (knowledge-base)
Citation Guidance
Explore pharmaceutical industry profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Cynapsus Therapeutics.
- Canonical profile: https://brandsource.ai/brands/cynapsus-therapeutics
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/cynapsus-therapeutics/json-ld
- Citation profile API: https://brandsource.ai/api/brands/cynapsus-therapeutics/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (94/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-21
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
Cynapsus is a specialty central nervous system, or CNS, pharmaceutical company developing a fast-acting, easy-to-use, sublingual thin film for the potential treatment for on-demand management of debilitating OFF episodes associated with Parkinson’s disease (PD). The Company successfully completed a Phase 2 clinical trial for its product candidate, APL-130277, a sublingual formulation of apomorphine hydrochloride, or apomorphine. Apomorphine is the only molecule approved for acute, intermit
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 4 supporting sources linked.
- 5 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.